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BACKGROUND: Obesity has reached global epidemic proportions in both adults and children and is associated with numerous comorbidities, 
including hypertension, type 2 diabetes mellitus (T2DM), 
dyslipidemia and major cardiovascular diseases (CVD).
CONTENT: Adiposity may cause adipocyte and adipose 
tissue anatomic and functional abnormalities, termed 
adiposopathy (adipose-opathy) or "sick fat," that result 
in endocrine and immune derangements. Adiposopathy 
may directly contribute to CVD through pericardiac and 
perivascular effects on the myocardium and blood vessels. 
Adiposopathy may also indirectly contribute to CVD through 
promoting or worsening major CVD risk factors such as 
T2DM, high blood pressure, and dyslipidemia. Despite this 
adverse association, numerous studies have documented an 
obesity paradox in which overweight and obese people with 
established CVD, including hypertension, heart failure, 
coronary heart disease, and peripheral arterial disease, 
have a better prognosis compared with nonoverweight/
nonobese patients. These paradoxical findings are made 
less paradoxical when the pathogenic potential of excessive 
body fat is assessed based on adipose tissue dysfunction 
rather than simply on increased fat mass alone.
SUMMARY: Adiposopathy is defined as pathological 
adipose tissue function that may be promoted and 
exacerbated by fat accumulation (adiposity) and sedentary 
lifestyle in genetically susceptible patients. Adiposopathy 
is a root cause of some of the most common metabolic 
diseases observed in clinical practice, including T2DM, 
hypertension and dyslipidemia. 
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LATAR BELAKANG: Obesitas telah mencapai epidemis secara global, baik pada anak maupun dewasa, dan obesitas berkaitan dengan berbagai 
komorbiditas meliputi hipertensi, diabetes melitus tipe 2 
(DMT2), dislipidemia, dan penyakit kardiovaskular  (PKV) 
mayor.
ISI: Adipositas dapat menyebabkan abnormalitas sel 
adiposit dan jaringan adiposa baik secara anatomi maupun 
fungsional, dan hal ini dikenal sebagai adiposopati (adiposa-
opati), atau “lemak yang sakit”, yang menyebabkan 
gangguan sistim endokrin dan imun. Adiposopati dapat 
berperan langsung terhadap PKV melalui efek pericardiac 
dan perivaskular pada otot jantung dan pembuluh darah. 
Adiposopati juga dapat mempengaruhi PKV secara tidak 
langsung dengan cara memperburuk faktor risiko PKV seperti 
DMT2, hipertensi, dan dislipidemia. Selain hubungan yang 
merugikan ini, banyak penelitian yang membuktikan suatu 
paradoks obesitas dimana subyek dengan kelebihan berat 
badan atau obesitas yang juga menderita PKV, termasuk 
hipertensi, gagal jantung, penyakit jantung koroner, dan 
penyakit arteri perifer, menunjukkan prognosis yang lebih 
baik dibandingkan dengan pasien tanpa kelebihan berat 
badan/obesitas. Penemuan paradoks ini menjadi kurang 
berarti jika kajian potensi patogenik kelebihan lemak tubuh 
didasarkan pada disfungsi jaringan lemak dan bukan pada 
peningkatan massa lemaknya saja.
RINGKASAN: Adiposopati didefinisikan sebagai disfungsi 
jaringan lemak yang patologis, dan dapat dipicu serta 
diperburuk oleh akumulasi lemak (adipositas) dan gaya 
hidup sedentary, pada pasien yang rentan secara genetik. 
Adiposopati merupakan akar penyebab berbagai penyakit 
metabolik yang ditemukan secara klinis, seperti DMT2, 
hipertensi dan dislipidemia.
Abstract Abstrak
R E V I E W  A R T I C L E
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Obesity is an epidemic. An increase in body fat in many 
individuals and populations directly increases the risk 
of metabolic diseases such as type 2 diabetes mellitus 
(T2DM), hypertension and dyslipidemia.(1,2) The increased 
prevalence of excessive visceral obesity and obesity related 
cardiovascular risk factors is closely associated with the 
rising incidence of cardiovascular diseases (CVD) and 
T2DM. This clustering of vascular risk factors in (visceral) 
obesity is often referred to as metabolic syndrome.(3-5)
 However, obesity itself is not yet universally recognised 
as a disease. A sole focus on body mass index (BMI) in 
attempting to define obesity as a disease is not adequate. 
A more rational approach is to evaluate excessive body fat 
for its pathogenic potential. This requires recognising that 
adipose tissue is an active endocrine and immune organ, 
and that pathological disruption of important adipose tissue 
metabolic processes is detrimental to patient health.(6-8) The 
failure to adequately recognise the physiologic importance 
of adipose tissue to metabolic health, both clinically and in 
the medical⁄endocrine literature, is significantly because of 
a failure of existing terminology to adequately describe the 
pathogenic potential of adipose tissue, and its contribution 
to metabolic disease.(9) 
 From a pathophysiological point of view, the ‘quality’ 
of adipose tissue is more important than the ‘quantity’. 
Nevertheless, a major driver of adipose tissue function is 
the quantity of visceral fat.(10) ‘Adiposopathy’ (adipose-
opathy) is a term used to describe the adverse anatomical 
and pathophysiologic consequences of pathogenic adipose 
tissue. From a patient standpoint, the term adiposopathy can 
be translated as representing ‘sick fat’.(11) These terms and 
this approach emphasise that adipose tissue has as much 
pathogenic potential to result in ill health as the pathologic 
dysfunction of other body tissues. Thus, ‘adiposopathy’ 
represents a ‘disease’ similar to other organopathies.(9)
Although obesity has been implicated as one of the major 
risk factors for hypertension, heart failure (HF) and coronary 
heart disease (CHD), evidence from clinical cohorts of 
patients with established CVD indicates an obesity paradox 
because overweight and obese patients with hypertension, 
HF, CHD, and peripheral arterial disease (PAD) tend to have 
a more favorable short and longterm prognosis.(12)
paradox, adipocyte dysfunction, adipose hypertrophy, 
adiposehyperplasia
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KATA KUNCI: adiposopati, adipositas, paradoks obesitas, 
disfungsi adiposit, hipertrofi adiposa, hiperplasia adiposa
Introduction
The etiology of obesity is multifactorial. However, the root 
cause is energy imbalance: more calories consumed than 
expended. Chronic imbalance of calories consumed vs 
expended causes increased storage of the excess energy in 
the form of adipocyte  intracellular triglyceride stores. The 
increase in fat mass manifests as both increased intracellular 
lipids and greater adipocyte size (hypertrophy) and increased 
numbers of adipocytes (hyperplasia).(13)
 During the past 10 years, the understanding of the 
physiological and pathophysiological role of the adipocyte 
has been completely changed. Once considered to be a 
passive type of connective tissue storing excess energy 
as triglycerides, adipose tissue has now been established 
as a real endocrine organ coupling (neuro)-endocrine and 
metabolic signaling.(14) Secretory products of preadipocytes 
and mature adipocytes, the so-called adipocytokines, clearly 
regulate energy homeostasis, appetite/satiety, reproduction, 
and insulin sensitivity and influence neuroendocrine, 
endothelial, immunological, hematological, angiogenetic, 
and vascular functions in an endocrine, paracrine, and 
autocrine manner.(15)
 Adipocytes typically constitute the majority of adipose 
tissue cellular content. Fat containing adipocytes constitute, 
by far, most of the adipose tissue volume. Adipocytes are 
surrounded by fibrous connective tissue, collagen, nerves, 
and blood vessels. Adipose tissue's supporting framework 
contains "stromal vascular fraction" cells, which include 
mesenchymal cells, fibroblasts, preadipocytes, endothelial 
precursor cells, smooth muscle cells, blood cells, and 
immune cells.(16) Previously, adipogenesis was thought 
to cease early in life, resulting in a fixed number of 
adipocytes that predestined individuals to be lean or obese. 
However, fat cell turnover is now known to be a dynamic 
process by which mesenchymal stem cells undergo lineage 
commitment, preadipocyte proliferation, growth arrest, and 
terminal differentiation into mature adipocytes. The number 
of adipocytes is therefore dependent on the balance between 
adipogenesis and apoptosis(17,18), with some suggesting 
that approximately 10% of fat cells are renewed annually 
at all adult ages and at all levels of body mass index (BMI).
(19)
 This has clinical implications because during 
Obesity
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positive caloric balance, adipocytes normally undergo 
initial hypertrophy, which elicits cellular signaling for the 
recruitment, proliferation, and differentiation of new fat 
cells. If adipogenesis proceeds unencumbered in peripheral 
subcutaneous adipose tissue, then adiposity may not 
cause demonstrable adipose tissue dysfunction or adverse 
metabolic consequences. Conversely, if adipogenesis 
is impaired, then the lack of adipocytes to adequately 
proliferate (or differentiate) may be pathophysiologically 
analogous to a relative lack of adipocytes, sometimes 
described as representing an acquired lipodystrophy.(20)
The lack of excess energy storage in new fat cells due 
to inadequate adipogenesis may cause existing fat cells 
to undergo excessive hypertrophy, causing adipocyte 
dysfunction and pathogenic adipocyte and adipose tissue 
endocrine and immune responses.(6,21) 
 Adipocytes become hypertrophic during the 
development of obesity, and  their  size  increases up to 140-
180 mm in diameter. Adipocytes have a limited capacity for 
hypertrophy; one reason for this is considered the diffusion 
limit of oxygen, which is at most 100 mm.  Therefore, it 
is possible that hypertrophic adipocytes might endure less 
than adequate oxygen supply.(22,23) Hypoxia occurs when 
oxygen availability does not match the demand of the 
surrounding tissue, resulting in decreased oxygen tension.
(24) An important and well characterized key regulator of 
the adaptive response to alterations in oxygen tension is 
hypoxia-inducible factor 1 (HIF1), a transcription factor 
that accumulates during hypoxia and increases the mRNA 
expression of a wide variety of genes that stimulate 
erythropoiesis, angiogenesis, and glycolysis.(25) Many 
disturbances including hypoxia cause accumulation of 
unfolded proteins in the endoplamic reticulum (ER), 
resulting in ER stress.(26)
 Thus, in states of energy imbalance and adiposity, 
excessive demands on the ER result in dysfunction of 
protein folding, lipid-droplet creation, and cholesterol 
sensing. Manifestations of adipocyte ER stress include 
increased lactate concentrations and production of CCAT/
enhancer  binding protein (C/EBP) homologous protein 
(CHOP). In mouse models, CHOP decreases production of 
adiponectin, and interfering with CHOP mRNA counteracts 
this decrease in adiponectin(24), providing insight into 
how intraorganelle dysfunction may be communicated 
systemically via circulating adipokines. Another cellular 
manifestation of ER stress is the “unfolded protein 
response” (UPR).(13) This state of ER stress, manifested 
by increased lactate, CHOP production, and activation 
of UPR, also may result in systemic release of free fatty 
acids and inflammatory mediators. (27) In short, if during 
Large studies of initially healthy men and women 
consistently link adiposity with an increased risk of 
cardiovascular events.(32,33) Compared with a reference 
body mass index (BMI),  <25 kg/m2, the relative risk of 
dying during the next decade ranges from 1.2 for over 
weight (25–29.9 kg/m2) to 3.8 for severely obese (>40 kg/
m2) subjects, after adjustment for age, smoking, alcohol 
and physical activity.(32) In striking contrast, among 
patients with known atherothrombotic diseases(34,35) or 
multiple risk factors(36), just the opposite is seen (‘obesity 
paradox’): the leanest fare worse(34) and the heavier fare 
better than the normal weight reference groups.(34-36)
 Obesity, hypertension, and the obesity paradox, 
despite having a higher prevalence of hypertension in 
obesity, recent data have shown an obesity paradox. Uretsky 
et al. investigated the effects of obesity on cardiovascular 
outcomes in 22,576 treated hypertensive patients with 
known CHD.(34) During 2-year follow up, all-cause 
mortality was 30% lower in overweight and obese patients, 
despite less effective blood pressure control in these patients 
compared with the normal weight group. A previous study 
also showed decreased stroke risk and total mortality 
among overweight patients compared with lean patients.
(37) Similarly, another major hypertension study showed 
a U-shaped relationship between all cause, cardiovascular, 
and non cardiovascular mortality and BMI, meaning 
excess mortality at both extremes of BMI.(38) In another 
study of 800 elderly hypertensive patients, total mortality 
and cardiovascular and non cardiovascular major events 
were highest in those with the leanest BMI quintile.(39) 
The association between BMI and major cardiovascular 
events was U-shaped, whereas non cardiovascular mortality 
decreased with increasing BMI. In aggregate, these studies 
suggest that although obesity may be a powerful risk factor 
for hypertension and left ventricular hypertrophy (LVH), 
obese hypertensive patients may paradoxically have a 
better prognosis, possibly because of having lower systemic 
vascular resistance and plasma renin activity compared with 
more lean hypertensive patients.(12,40)
 Obesity, HF, and the obesity paradox, in a study of 
5,881 Framingham Heart Study participants, Kenchaiah 
positive caloric balance, any stage of the adipogenic 
processes is impaired (recruitment, proliferation(28) or 
differentiation(29-31), then this may lead to pathologic 
adipose tissue endocrine and immune responses that 
contribute to metabolic disease, particularly in individuals 
who are genetically or environmentally predisposed.(6)
Obesity Paradox
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et al. showed that during a 14-year follow-up, for every 1 
kg/m2 increment in BMI, the risk of HF increased 5% in 
men and 7% in women. In fact, a graded increase in the risk 
of HF was observed across all categories of BMI.(12,41) 
Despite the known adverse effects of obesity on both 
systolic and particularly diastolic cardiovascular function 
and the epidemiologic data showing a strong link between 
obesity, generally defined by BMI criteria, and HF, many 
studies have suggested that obese HF patients had a better 
prognosis (Figure 1).(42) In a recent meta-analysis of 9 
observational HF studies (n=28,209) in which patients were 
followed up for an average of 2.7 years, Oreopoulos et al., 
showed that compared with individuals without elevated 
BMI, overweight and obese HF patients had reductions in 
cardiovascular (19 and 40%, respectively) and reduction all 
cause mortality 16 and 33% respectively.(43) 
 Obesity, CHD, and the obesity paradox, obesity plays 
a major role in adversely affecting major CHD risk factors, 
including hypertension, dyslipidemia, and T2DM, is the 
major component of metabolic syndrome, and is probably 
an independent risk factor for atherosclerosis and CHD 
events.(41,44-46) Nevertheless, as with hypertension and 
HF, many studies have also reported an obesity paradox in 
CHD, including in patients treated with revascularization 
(44,47).
 In a recent systematic review of over 250,000 patients 
in 40 cohort studies followed up for 3.8 years, Romero-
Corral et al. reported that overweight and obese CHD 
patients have a lower risk for total and cardiovascular 
mortality compared with underweight and normal-weight 
CHD patients.(12,47) Importantly, the obesity paradox has 
also been shown in patients after myocardial infarction and 
revascularization, and more recently has been shown in 
patients referred for exercise stress testing.(47,48) Although 
the mechanism for this effect is uncertain, in aggregate, these 
studies suggest that despite the fact that obesity increases 
the risk for developing CHD, at least overweight and mild 
obesity do not seem to adversely affect prognosis in patients 
with established CHD.(12)
 Obesity paradox in other cardiovascular populations. 
Galal et al., have recently assessed 4.4 year mortality 
in 2,392 patients with PAD who had undergone major 
vascular surgery and had high mortality risk during follow-
up. This study also showed a powerful obesity paradox, 
with progressive reductions in mortality in normal BMI, 
overweight, and obese groups compared with underweight 
patients.(12,49)
 Although it is debated to what extent diabetes, 
sedentary lifestyle, hypertension, and dyslipidemia (often 
associated with adiposity and not always corrected for in 
data analyses) contribute to cardiovascular risk, fatness 
remains a strong harbinger of cardiovascular events among 
initially healthy subjects, especially when co-inflammation 
favours the ‘unhealthy fat’ phenotype (Figure 3).(50,51) 
At the same time, adipose tissue, while increasing the 
probability of developing atherothrombosis, may offer 
protection in the context of tissue damage, supporting 
the aphorism ‘survival of the fattest’. Possible defences 
conferred by adiposity include regenerative, metabolic, and 
Figure 1. Risk-adjusted survival curves for the 4 body mass 
index categories at 5 years in a study of 1,203 individuals with 
moderate to severe HF.(12) (Adapted with permission from 
Elsevier Inc.).
Figure 2. Body Composition and HF Prognosis.(12) (Adapted 
with permission from Elsevier Inc.)
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haemodynamic compensation, and/or reversal to a ‘healthy 
fat’ phenotype (Figure 3). Thus, a condition signalling risk 
would confer protection in the midst of disease, just as 
pre-infarction unstable angina, while heralding thrombotic 
complications, protects myocardium against prolonged 
ischaemia.(34,51,52)
 Overwhelming evidence supports the importance 
of obesity in the pathogenesis and progression of CVD. 
Although an obesity paradox exists, in that overweight and 
obese patients with established CVD seem to have a more 
favorable prognosis than leaner patients, the constellation 
of data still support purposeful weight reduction in the 
prevention and treatment of CVD.(12)
Adiposity is excessive adipose tissue. Those with adiposity 
are characterized as being overweight or obese. Obesity is 
described as an independent risk factor for CVD. Adiposity 
is pathological to the cardiovascular system through 
excessive fat-mass mechanisms and through adipocyte and 
adipose tissue dysfunction.(6,16) Adipose tissue may be 
pathogenic though the adverse consequences of excessive 
fat mass alone, and/or though deleterious endocrinologic and 
immunologic activity. Adipocyte hyperthrophy and viceral 
adipose tissue accumulation are ascocieted with many of the 
most common metabolic disease found in clinical practice, 
including T2DM, hypertension, dyslipidemia and possibly 
atherosclerosis.(53,54)
  “Disease” can be defined as an impairment of body 
function or system, often accompanied by pathological 
alterations in tissues or cell, resulting in adverse clinical 
outcomes.(55) If adipocyte hypertropthy and visceral 
adipose tissue accumulation occur during positive caloric 
balance, then the pathogenic consequences may unfavorably 
affect other body organs, such as liver, muscle, and pancreas, 
resulting in adverse clinical outcomes.(2) It is, therefore, 
through the understanding of the pathogenic potential of 
hypertrophied adipocytes and increased accumulation of 
visceral adipose tissue that helps support how an increase 
in body fat, in many individuals, is itself a disease. It 
also provides a framework for explaining why treating 
pathogenic adipose tissue is more rational than treating BMI 
alone.(8)
 It was through decades of adipose tissue scientific 
research and the acknowledgment of the importance of 
central adiposity by major scientific organizations that the 
term “adiposopathy” arose.(11) Cardiomyopathy describes 
the pathologic enlargement of heart cells and the heart organ, 
which results in anatomic/functional abnormalities leading 
to adverse clinical consequences. Similarly, adiposopathy 
describes the pathogenic enlargement of fat cells and fat 
tissue, which results in anatomic/functional abnormalities 
leading to adverse clinical consequences, including the most 
common metabolic diseases encountered in clinical practice 
(e.g., T2DM, high blood pressure, dyslipidemia).(56)
 Adiposopathy (or "sick fat") is defined as pathologic 
adipose tissue anatomic/functional disturbances promoted by 
positive caloric balance in genetically and environmentally 
susceptible individuals that result in adverse endocrine and 
Figure 3. Unhealthy vs healthy fat 
phenotype.(15) (Adapted with permission 
from European Society of Cardiology) 
Adiposopathy
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immune responses that may directly promote CVD, and may 
cause or worsen metabolic disease. Because many of these 
metabolic diseases are major CVD risk factors (e.g., T2DM, 
high blood pressure, and dyslipidemia), adiposopathy also 
indirectly increases CVD risk.(21)
 Adiposopathy is anatomically manifested by adipocyte 
hypertrophy, visceral adiposity and ⁄or ectopic fat deposition, 
which physiologically results in adverse endocrine and 
immune consequences leading to metabolic disease.(9) The 
clinical importance of adiposity is not only how fat is stored 
(i.e., adipocyte proliferation vs. adipocyte hypertrophy), 
but also where fat is stored. Visceral adipose tissue may be 
more metabolically active than subcutaneous adipose tissue, 
and these depots inherently differ in processes involving 
lipolysis/lipogenesis, expression of adipocyte receptors, and 
differ in the secretion of adipokines/cytokines, enzymes, 
Figure 4. Adiposopathy: simplified relationship between pathogenic adipose tissue and cardiovascular disease.(21) (Adapted with 
permission from Elsevier Inc.)
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hormones, immune molecules, proteins, and other factors.
(6) Derangements in adipose tissue endocrine and immune 
processes contribute to metabolic disease.(53) Pericardial 
and perivascular adiposopathy may have direct pathogenic 
effects on the myocardium, coronary arteries, and peripheral 
vessels via dysregulated local secretion of vasoactive and 
inflammatory factors that may contribute to atheroma 
instability and other cardiovascular pathophysiology.(57-
61)
 Although adipocyte and adipose tissue dysfunction 
are often etiologic, adiposopathy alone does not cause 
or worsen metabolic disease. Instead, the clinical 
consequences of "sick fat" depend on how adipose tissue 
interacts or undergoes "cross talk" with other body organs 
such as the liver, muscle, pancreas, as well as organs of the 
cardiovascular, endocrine, immune, nervous, genitourinary, 
gastrointestinal, integumentary, and other body systems.
(62) In summary, fat weight gain leading to metabolic 
disease is most dependent upon how fat is stored (adipocyte 
hypertrophy vs. adipocyte proliferation), where the fat is 
stored (visceral vs. other fat depots), and adipose tissue 
signalling and interactions with other body organs.
 Various obesity paradoxes are described when 
increased body fat mass does not increase morbidity or 
mortality, when a decrease in excessive body fat does not 
improve patient health, or when an increase in body fat 
mass actually reduces morbidity or mortality. Many of 
these apparent clinical contradictions are mitigated if the 
pathogenic potential of excess adipose tissue is assessed 
not solely by adiposity, but also by adiposopathy. This 
also helps explain paradoxical populations described as 
"metabolically healthy, but obese", "metabolically obese, 
normal weight"(7), and the increased risk of T2DM among 
Pima Indians(6,63). Adiposopathy also helps explain 
the otherwise curious (paradoxical) use of "ectopic fat" 
to describe excessive fat deposition in any body organ, 
including increased fat deposition in fat depots (e.g., visceral 
adipose tissue)(64-66) and helps identify when adiposity or 
obesity might best be considered a disease (9,67,68).
 The adipocentric paradigm provides the basis for 
a unifying, pathophysiological process whereby fat gain 
in susceptible patients leads to fat dysfunction ('sick fat'), 
and wherein pathological abnormalities in fat function 
(adiposopathy) are more directly related to the onset 
of excessive fat related metabolic diseases (EFRMD) 
than increases in fat mass (adiposity) alone. But just as 
worsening fat function worsens EFRMD, improved fat 
function improves EFRMD. Peroxisome proliferator-
activated receptor-gamma agonists increase the recruitment, 
proliferation and differentiation of preadipocytes ('healthy 
fat') and cause apoptosis of hypertrophic and dysfunctional 
(including visceral) adipocytes resulting in improved fat 
function and improved metabolic parameters associated 
with EFRMD.(69)Adiposopathy: Replacing the Term "Metabolic Syndrome"
Many authors and scientific organizations have characterized 
and applied terminology to the constellation of metabolic 
abnormalities often associated with the accumulation of 
excessive body fat. Unfortunately, not everyone agrees on 
any particular characterization, nor do they always agree 
upon the definition. The most common current term that 
refers to the cluster of metabolic abnormalities associated 
with disorders in glucose metabolism, hypertension and 
dyslipidemia is the ‘metabolic syndrome’. A similar clinical 
presentation has also been termed atherothrombogenic 
syndrome, cardiovascular metabolic syndrome, deadly 
quartet (obesity, hyperinsulinemia, hypertension and 
dyslipidemia), dysmetabolic syndrome, syndrome X, 
insulin resistance syndrome. The variety of different terms 
for a similar or related condition reflects the difficulty 
in applying one name to a constellation of related, and 
sometimes unrelated metabolic abnormalities, and reflects 
an unsatisfying attempt to identify one root pathophysiologic 
cause of all of these. Given the enormity of this disease 
burden and the known public health consequences, it 
would seem reasonable that extraordinary efforts be made 
towards preventing, treating, and potentially curing the 
metabolic syndrome. However, the conduct and reporting 
of clinical trials to demonstrate efficacy in the treatment of 
the metabolic syndrome have been hampered by the lack 
of consistent terminology, the lack of uniform diagnostic 
definitions and the different criteria reported in different 
clinical studies.(11)
 Further complicating the matter is that not all clinicians 
are clear on the similarities and differences between the 
metabolic syndrome and other associated conditions. Not 
all clinicians are aware that patients with T2DM may or may 
not have metabolic syndrome, and patients with metabolic 
syndrome may or may not have diabetes. Moreover, even 
researchers are not certain whether insulin resistance 
syndrome and metabolic syndrome are the same, or have 
the same treatment goals.(70) It is also noteworthy that 
the scientific organizations that have defined metabolic 
syndrome have not required that the components of 
the metabolic syndrome be due to any unifying and 
underlying metabolic process. This lack of indication 
criteria for the treatment of the metabolic syndrome impairs 
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the development of pharmaceutical agents to treat the 
underlying root cause and/or pathophysiology, and instead 
promotes continued research efforts focusing on drug 
treatment for the components of the metabolic syndrome. 
Accumulating scientific data suggest that in most patients, 
it is the dysfunction of adipose tissue (adiposopathy) that is 
the root mechanistic aetiology of abnormalities of glucose 
metabolism, blood pressure and lipid metabolism.(11)
 If it becomes generally accepted that dysfunction of 
adipose tissue is the root mechanistic pathophysiologic 
aetiology of the metabolic abnormalities that compose the 
metabolic syndrome in the majority of patients, then it may 
be time to replace the term metabolic syndrome (a term 
largely reflective of sometimes unrelated consequence), 
and replace it with ‘adiposopathy’ (a term more focused 
on unified underlying causality). It may then be time to 
focus on adiposopathy as a primary treatment target, and to 
establish clear criteria for its diagnosis, and for granting an 
indication for its treatment.(11)
Adipocyte hypertrophy and visceral adiposity may 
contribute (‘‘cause’’) metabolic diseases such as T2DM, 
hypertension, and dyslipidemia. Adiposopathy and ‘‘sick 
fat’’ are scientific and clinical terms, respectively, that 
help define when excessive body fat is a metabolic and 
cadiovascular disease.
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